News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
690,429 Results
Type
Article (39664)
Company Profile (284)
Press Release (650481)
Section
Business (204130)
Career Advice (2007)
Deals (35409)
Drug Delivery (91)
Drug Development (81500)
Employer Resources (168)
FDA (16288)
Job Trends (14823)
News (345769)
Policy (32638)
Tag
Academia (2536)
Alliances (49277)
Alzheimer's disease (1275)
Approvals (16249)
Artificial intelligence (147)
Bankruptcy (354)
Best Places to Work (11595)
Biotechnology (199)
Breast cancer (194)
Cancer (1408)
Cardiovascular disease (120)
Career advice (1671)
Cell therapy (286)
Clinical research (65293)
Collaboration (494)
Compensation (286)
COVID-19 (2555)
C-suite (111)
Data (1407)
Diabetes (181)
Diagnostics (6184)
Earnings (84976)
Employer resources (146)
Events (110303)
Executive appointments (410)
FDA (16991)
Funding (446)
Gene therapy (201)
GLP-1 (630)
Government (4351)
Healthcare (18754)
Infectious disease (2649)
Inflammatory bowel disease (114)
Interviews (313)
IPO (16378)
Job creations (3626)
Job search strategy (1424)
Layoffs (422)
Legal (7891)
Lung cancer (204)
Manufacturing (212)
Medical device (13227)
Medtech (13232)
Mergers & acquisitions (19230)
Metabolic disorders (478)
Neuroscience (1605)
NextGen: Class of 2025 (6513)
Non-profit (4474)
Northern California (1742)
Obesity (273)
Opinion (185)
Parkinson's disease (100)
Patents (124)
People (56539)
Phase I (20257)
Phase II (28752)
Phase III (21475)
Pipeline (521)
Postmarket research (2594)
Preclinical (8570)
Radiopharmaceuticals (237)
Rare diseases (271)
Real estate (5893)
Regulatory (21861)
Research institute (2315)
Resumes & cover letters (351)
Southern California (1510)
Startups (3565)
United States (15549)
Vaccines (567)
Weight loss (193)
Date
Today (164)
Last 7 days (306)
Last 30 days (1802)
Last 365 days (34758)
2025 (290)
2024 (35332)
2023 (40175)
2022 (51288)
2021 (55827)
2020 (54174)
2019 (46657)
2018 (35113)
2017 (32197)
2016 (31584)
2015 (37638)
2014 (31442)
2013 (26459)
2012 (28651)
2011 (29355)
2010 (27428)
Location
Africa (716)
Arizona (197)
Asia (37660)
Australia (6153)
California (3935)
Canada (1484)
China (334)
Colorado (174)
Connecticut (182)
Europe (80378)
Florida (555)
Georgia (137)
Illinois (395)
Indiana (229)
Maryland (649)
Massachusetts (3025)
Michigan (177)
Minnesota (297)
New Jersey (1128)
New York (1117)
North Carolina (751)
Northern California (1742)
Ohio (148)
Pennsylvania (947)
South America (1095)
Southern California (1510)
Texas (567)
Utah (111)
Washington State (405)
690,429 Results for "anges mg inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dr. Reddy’s Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
November 26, 2024
·
3 min read
Pharm Country
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.
June 24, 2024
·
9 min read
Business
Senores Pharmaceuticals, Inc. announces the launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg in the U.S. market
Senores Pharmaceuticals, Inc. announced the launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg, a bioequivalent and therapeutically equivalent to Cardene Capsules, 20 mg and 30 mg, of Chiesi USA , Inc. in the U.S. market.
September 25, 2023
·
1 min read
Press Releases
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF NYMALIZE® (NIMODIPINE) ORAL SOLUTION 30 MG/5 ML PREFILLED ENFIT® SYRINGE
September 3, 2024
·
3 min read
Press Releases
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study
December 4, 2024
·
3 min read
Pharm Country
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA ® HD (aflibercept) Injection 8 mg.
April 29, 2024
·
17 min read
Dr. Reddy’s Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Dr. Reddy’s Laboratories Ltd. today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).
May 3, 2024
·
3 min read
Pharm Country
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
Aprea Therapeutics, Inc. today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment.
May 28, 2024
·
7 min read
Genetown
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
scPharmaceuticals Inc. today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.
April 24, 2024
·
7 min read
Pharm Country
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due To Failed Dissolution
Glenmark Pharmaceuticals Inc. is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules, USP 10 mEq K, to the consumer level.
June 25, 2024
·
13 min read
1 of 69,043
Next